Literature DB >> 25113621

Clinical pregnancy in a woman with idiopathic hypogonadotropic hypogonadism and low AMH: utility of ovarian reserve markers in IHH.

Crystal Chan1, Kimberly Liu.   

Abstract

OBJECTIVE: Serum anti-mullerian hormone (AMH) has been proposed as a useful marker of ovarian reserve that is cycle-independent and predictive of outcome in assisted reproduction cycles. However, there is evidence that AMH production is gonadotropin-dependent, and that under the influence of FSH, growing follicles contribute to circulating AMH levels. Therefore, AMH testing may not be universally reflective of the primordial follicle pool in certain conditions. We demonstrate that in patients with idiopathic hypogonadotropic hypogonadism (IHH) and deficient gonadotropin production, AMH and antral follicle count (AFC) may not be reliable markers of ovarian reserve.
DESIGN: Case report.
SETTING: Fertility clinic at a tertiary academic hospital. PATIENT: A 30-year-old nulligravid patient with IHH who presented for fertility treatment with low FSH (0.3 IU/L), LH (0.1 IU/L), estradiol (77 pmol/L) and AMH levels (0.65 pmol/L), and an unmeasurable AFC. INTERVENTION: A three-month course of priming with oral micronized 17β-estradiol, followed by daily injections of human menopausal gonadotropins (hMG). MAIN OUTCOME MEASURE: AMH level and follicular development.
RESULTS: After 60 days of stimulation with hMG, the patient's AMH level increased to a peak of 1.27 pmol/L. After 102 days of stimulation, her estradiol level rose to 480 pmol/L and a 19 mm dominant follicle was detected. The patient successfully conceived with intrauterine insemination.
CONCLUSION: Ovarian reserve testing in patients with IHH can be challenging due to the contracted appearance of the ovaries and deficient FSH production. In these patients, AMH levels may underestimate ovarian reserve due to the lack of FSH-dependent growing follicles. When treated with a long course of hMG, these patients may exhibit increased AMH levels and demonstrate adequate follicular development.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25113621      PMCID: PMC4171405          DOI: 10.1007/s10815-014-0312-2

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  23 in total

1.  Serum anti-Müllerian hormone dynamics during controlled ovarian hyperstimulation.

Authors:  Renato Fanchin; Luca Maria Schonäuer; Claudia Righini; Nelly Frydman; René Frydman; Joëlle Taieb
Journal:  Hum Reprod       Date:  2003-02       Impact factor: 6.918

2.  What does anti-Müllerian hormone tell you about ovarian function?

Authors:  Richard A Anderson
Journal:  Clin Endocrinol (Oxf)       Date:  2012-11       Impact factor: 3.478

Review 3.  Approach to the patient with hypogonadotropic hypogonadism.

Authors:  Letícia Ferreira Gontijo Silveira; Ana Claudia Latronico
Journal:  J Clin Endocrinol Metab       Date:  2013-05       Impact factor: 5.958

4.  Anti-mullerian hormone as a predictor of time to menopause in late reproductive age women.

Authors:  Ellen W Freeman; Mary D Sammel; Hui Lin; Clarisa R Gracia
Journal:  J Clin Endocrinol Metab       Date:  2012-02-29       Impact factor: 5.958

5.  Serum müllerian-inhibiting substance levels during normal menstrual cycles.

Authors:  C L Cook; Y Siow; S Taylor; M E Fallat
Journal:  Fertil Steril       Date:  2000-04       Impact factor: 7.329

6.  Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles.

Authors:  David B Seifer; David T MacLaughlin; Benjamin P Christian; Bo Feng; Robert M Shelden
Journal:  Fertil Steril       Date:  2002-03       Impact factor: 7.329

7.  Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment.

Authors:  Christien Weenen; Joop S E Laven; Anne R M Von Bergh; Mark Cranfield; Nigel P Groome; Jenny A Visser; Piet Kramer; Bart C J M Fauser; Axel P N Themmen
Journal:  Mol Hum Reprod       Date:  2004-02       Impact factor: 4.025

8.  Reference range for the antimüllerian hormone Generation II assay: a population study of 10,984 women, with comparison to the established Diagnostics Systems Laboratory nomogram.

Authors:  Scott M Nelson; Stamatina Iliodromiti; Richard Fleming; Richard Anderson; Alex McConnachie; Claudia-Martina Messow
Journal:  Fertil Steril       Date:  2013-11-09       Impact factor: 7.329

9.  Expression of the mouse anti-müllerian hormone gene suggests a role in both male and female sexual differentiation.

Authors:  A Münsterberg; R Lovell-Badge
Journal:  Development       Date:  1991-10       Impact factor: 6.868

10.  Which follicles make the most anti-Mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection.

Authors:  J V Jeppesen; R A Anderson; T W Kelsey; S L Christiansen; S G Kristensen; K Jayaprakasan; N Raine-Fenning; B K Campbell; C Yding Andersen
Journal:  Mol Hum Reprod       Date:  2013-04-04       Impact factor: 4.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.